Portage Biotech Inc ( (PRTG) ) has provided an announcement.
On March 7, 2025, Portage Biotech Inc.’s board of directors approved a new compensation plan for its directors, which includes an annual cash fee of $30,000 and an additional $25,000 fee upon the completion of a reverse merger or similar transaction. Additionally, the board authorized the issuance of 160,000 stock options to directors, officers, and employees under the 2021 Equity Incentive Plan, with specific vesting schedules and conditions. These strategic decisions aim to align the interests of the company’s leadership with its long-term goals and enhance its competitive positioning in the biotechnology sector.
More about Portage Biotech Inc
Portage Biotech Inc. is a company operating in the biotechnology industry, focusing on developing and commercializing innovative therapies. The company is based in the British Virgin Islands and is involved in advancing its portfolio of immuno-oncology assets.
YTD Price Performance: -17.01%
Average Trading Volume: 725,266
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.67M
See more data about PRTG stock on TipRanks’ Stock Analysis page.